AngioDynamics Reaffirms FY24 Sales Of $328M-$333M Vs. Consensus Of $328.56M, Adjusted EPS Loss Of $(0.28)-$(0.34) Vs. Consensus Of $(0.32)
Portfolio Pulse from Benzinga Newsdesk
AngioDynamics has reaffirmed its fiscal year 2024 net sales to be in the range of $328 to $333 million, with a gross margin of approximately 50% to 52% and an adjusted loss per share in the range of $0.28 to $0.34. These figures are in line with consensus estimates. The company's FY23 pro forma revenue, gross margin, and adjusted loss per share, excluding assets divested to Merit Medical, were $306.3 million, 50.5%, and $0.43, respectively.
October 04, 2023 | 11:11 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
AngioDynamics' reaffirmed FY24 sales and adjusted EPS loss are in line with consensus estimates, indicating stability in the company's financial outlook.
AngioDynamics' reaffirmed FY24 sales and adjusted EPS loss are in line with consensus estimates. This suggests that the company's financial outlook is stable, which could maintain investor confidence and have a neutral impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100